| abstract |
The present invention relates to a stable crystalline form of N- (3-ethynylphenyl) -6,7-bis (2-methoxyethoxy) -4-quinazolinamine hydrochloride designated as polymorph B, its products in essentially pure form and its use. The invention also relates to pharmaceutical compositions containing a stable form of polymorph B of N- (3-ethynylphenyl) -6,7-bis (2-methoxyethoxy) -4-quinazolinamine as hydrochloride, as well as other forms of compounds and their use in the treatment of hyperproliferative disorders. such as cancer. [The present invention relates to a stable crystalline form of N- (3-ethynylphenyl) -6,7-bis (2-methoxyethoxy) -4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form , and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N- (3-ethynylphenyl) -6,7-bis (2-methoxyethoxy) -4- quinazolinamine as hydrochloride, as well as other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound. |